Spironolactone Does Not Prevent Diabetic Nephropathy in Type 2 Diabetes
In a study, spironolactone treatment was not significantly better than placebo in preventing diabetic nephropathy in patients with high-risk type 2 diabetes.
In a study, spironolactone treatment was not significantly better than placebo in preventing diabetic nephropathy in patients with high-risk type 2 diabetes.
WASHINGTON—Canagliflozin showed a protective effect against kidney function decline in patients with type 2 diabetes and a baseline estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m2, new study findings presented at the American Society of Nephrology’s Kidney Week 2019 meeting suggest. The findings are from a post-hoc subgroup analysis of the phase 3 CREDENCE…
Sweden’s lower HbA1c target values not linked to further organ protection
FDA’s approval of canagliflozin for slowing progression of diabetic nephropathy in patients with type 2 diabetes makes the drug the first new treatment option in nearly 20 years indicated for slowing diabetic kidney disease in these patients.
Continued monotherapy with metformin, compared with a sulfonylurea, is associated with a lower risk for major adverse cardiovascular events (MACE) among patients with type 2 diabetes who experienced reduced kidney function.
New review identifies benefits of sodium-glucose co-transporter-2 (SGLT2) inhibitors at almost all levels of kidney function.
Machine learning algorithms can aid in assessment of renal histopathology
Testing for acid load needed in patients with diabetes taking sodium-glucose cotransporter-2 inhibitors
Studies document renal benefits of canagliflozin, dapagliflozin, empagliflozin, and dulaglutide
In a phase 2 study of patients with early diabetic nephropathy, esaxerenone decreased microalbuminuria in a dose-dependent manner over 12 weeks compared with placebo.